The new generation of cyber crime is shrewd. Are you protected?

2006-10-12 News Release

Web www.jobwerx.com jobwerx.tradepub.com

Search Jobwerx The Engineering Web

Pharmaceuticals duo announce drug to treat schizophrenia

Bifeprunox, a new drug application for treatment of schizophrenia, has been annouced jointly by Solvay and Wyeth Pharmaceuticals companies.

A New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational, new generation atypical antipsychotic for treatment and maintenance of stability of schizophrenic patients by Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals.

Find Information and Suppliers of schizophrenia medications.

The NDA submission is based on safety and efficacy studies that evaluated bifeprunox for the treatment of schizophrenia in approximately 2,550 patients. Patients were evaluated with acute exacerbations for six weeks, and stable patients were evaluated for six months

Schizophrenia is a chronic form of psychosis that develops in approximately three million North Americans. It is characterized by positive and negative symptoms such as hallucinations, delusions, poverty of speech, disorganized thought and emotional blunting. Severity of the symptoms, and the long-term pattern of schizophrenia, often cause a high degree of disability for patients and place a burden on families, caregivers and communities. Medications for schizophrenia can help reduce and control the distressing symptoms of the illness.

“The NDA submission of bifeprunox is an important milestone in our commitment to develop and commercialize compounds that potentially address the long-term treatment outcomes of patients with mental illnesses,” says Laurence Downey, M.D., President and CEO of Solvay Pharmaceuticals, Inc. “In addition to our research in schizophrenia, we’re also exploring treatments for other psychiatric disorders.”

“One recent U.S. government sponsored study, CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness), showed a significant need for new treatment options, especially over the long-term1 ,”says Joseph Camardo, M.D., Senior Vice President of Global Medical Affairs, Wyeth Pharmaceuticals. “We are pleased that our collaboration with Solvay Pharmaceuticals has resulted in an application with proposed indications for both initial therapy and maintenance, which is an important feature for an atypical antipsychotic.”

In March 2004, Solvay Pharmaceuticals and Wyeth entered into a collaboration agreement exclusively dedicated to neuroscience research and development. Under the terms of the agreement, the partners will codevelop and cocommercialize bifeprunox and two other compounds, currently known as SLV-313 and SLV-314, which are in earlier stages of development as treatments for schizophrenia, bipolar disorder, major depressive disorder with psychotic features and other indications.

Find Information about Solvay Group.

Read a recent press release about - An international chemicals and pharmaceutical group, Solvay, offers an innovative e-billing solution to its customers while complying with strict European Union requirements.

Pharmaceuticals Jobs - Post Employment Opportunity!

E-mail this page to a friend

- Antimicrobials solutions for medical device applications

- Certification, Training and Courses from The American Management Association

- Looking for a Study Program?

- All this Months News

- Changing Jobs? View
Homes for Sale in the U.S.

 

- Buy Golf Equipment Direct
from the Manufacturer and Save!

-

Copyright - Unless otherwise stated all contents of this web site are © 1998/2006 JOBWERX.COM. – All Rights Reserved. For permission to reproduce any contents of this web site, please advise our Syndication department: Log onto HELP